Nintedanib DPI (MNKD-201): Inhaled Delivery Innovation in IPF
- Exploring the scientific basis for dry powder inhalation of nintedanib and how targeted pulmonary delivery aims to maximize local exposure while potentially improving tolerability and expanding therapeutic window relative to oral antifibrotics
- Providing an update on the Phase 2 INFLO-2 study design and interim findings, including study endpoints, safety/tolerability observations, lung function trajectories, and how trial learnings are shaping expectations for inhaled antifibrotic therapy
- Considering what an efficacious inhaled antifibrotic means for the IPF treatment paradigm, including potential effects on standard of care sequencing, combination approaches with oral therapies, patient preference/adherence, and how delivery innovation may inform future antifibrotic development strategies